Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer Recurrence: A Meta-Analysis - Positive Notes

A meta-analysis was performed to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in men with oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) (how much radiation to use) and local control (LC) (the success of the radiation treatment in controlling the existing metastases as well as the development of new local metastases).  

Twenty-three observational studies with a total of 1441 lesions treated were included in the meta-analysis. 

The investigators found that the LC rate with SBRT was excellent, and there was minimal severe acute/late toxicity. They also found that their data suggest a dose relationship between BED and LC, with BED >100 Gy3 resulting in better rates of LC.

If you do experience an oligometastatic prostate cancer recurrence, you should consider as one of your treatment options SBRT.  

American journal of clinical oncology. 2019 Dec 04 [Epub ahead of print]  Gustavo A Viani, Caio V Arruda, Ana C Hamamura, Alexandre C Faustino, Anielle Freitas Bendo Danelichen, Flavio S Guimarães

School of Medicine of Ribeirão Preto-University of São Paulo (FMRP-USP), Ribeirão Preto., Bioscience Institute of University of State from Sao Paulo (UNESP), Botucatu, São Paulo, Brazil.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/31809327